As of January 22, 2025, BioLineRx (BLRX) has a market cap of $22.228 million USD. According to our data, BioLineRx is ranked No.8560 in global market value.
Year | Market Cap | %Change |
---|---|---|
Jan 22, 2025 | $22.23 M |
-25.64%
|
Dec 31, 2024 | $29.89 M |
-86.62%
|
Dec 29, 2023 | $0.22 B |
166.10%
|
Dec 30, 2022 | $83.98 M |
-71.08%
|
Dec 31, 2021 | $0.29 B |
-19.05%
|
Dec 31, 2020 | $0.36 B |
12.00%
|
Dec 31, 2019 | $0.32 B |
-65.91%
|
Dec 31, 2018 | $0.94 B |
-59.63%
|
Dec 29, 2017 | $2.33 B |
18.48%
|
Dec 30, 2016 | $1.96 B |
-29.23%
|
Dec 31, 2015 | $2.78 B |
-19.75%
|
Dec 31, 2014 | $3.46 B |
-42.35%
|
Dec 31, 2013 | $6.00 B |
11.07%
|
Dec 31, 2012 | $5.40 B |
-20.19%
|
Dec 30, 2011 | $6.77 B |
100%
|
Name | Market Cap | Market cap difference | Regions |
---|---|---|---|
Gilead Sciences
GILD
|
$116.07 B |
0.004 M
|
USA
|
Amgen
AMGN
|
$147.53 B |
0.002 M
|
USA
|
Biogen
BIIB
|
$20.80 B |
-0.001 M
|
USA
|
Regeneron Pharmaceuticals
REGN
|
$75.23 B |
1.245 B
|
USA
|
Vertex Pharmaceuticals
VRTX
|
$110.70 B |
-0.001 M
|
USA
|
Moderna
MRNA
|
$14.88 B |
0.000 M
|
USA
|
BioMarin Pharmaceutical
BMRN
|
$11.81 B |
-0.000 M
|
USA
|
Incyte
INCY
|
$14.05 B |
-0.000 M
|
USA
|
Alnylam Pharmaceuticals
ALNY
|
$34.39 B |
-0.001 M
|
USA
|
Ionis Pharmaceuticals
IONS
|
$5.19 B |
0.000 M
|
USA
|
Sarepta Therapeutics
SRPT
|
$11.08 B |
-0.000 M
|
USA
|
bluebird bio
BLUE
|
$77.02 M |
0.000 M
|
USA
|
CRISPR Therapeutics
CRSP
|
$3.82 B |
6.828 M
|
Switzerland
|
Editas Medicine
EDIT
|
$0.10 B |
-0.000 M
|
USA
|
Intellia Therapeutics
NTLA
|
$1.03 B |
0.000 M
|
USA
|
Market Cap | = | BLRX Stock Price | * | BLRX Shares Outstanding |
= | $0.11 | * | 0.14 B | |
= | $22.23 M |